1 10 years of health-care reform in China: progress and gaps in Universal Health Coverage
来源:LANCET( P 0140-6736 E 1474-547X ) 发表时间: 2019/09
类型:期刊论文 为本人加分:26774.931662
贡献度:参与作者
2 Realignment of incentives for health-care providers in China
来源:LANCET( P 0140-6736 E 1474-547X ) 发表时间: 2010/03
类型:期刊论文 为本人加分:14274.720562
3 Early appraisal of China's huge and complex health-care reforms
来源:LANCET( P 0140-6736 E 1474-547X ) 发表时间: 2012/03
类型:期刊论文 为本人加分:7412.825205
贡献度:参与作者
4 Systematic Review on Irrational Use of Medicines in China and Vietnam
来源:PLOS ONE( P 1932-6203 E ) 发表时间: 2015/03
类型:期刊论文 为本人加分:7056.180255
贡献度:共同通讯作者
5 Assessment of Total Economic Burden of Chronic Hepatitis B (CHB)-Related Diseases in Beijing and Gua..
来源:VALUE HEALTH( P 1098-3015 E 1524-4733 ) 发表时间: 2009/11
类型:期刊论文 为本人加分:5947.402093
贡献度:单独通讯作者
6 Disease burden of COPD in China: a systematic review
来源:INT J CHRONIC OBSTR( P 1178-2005 E ) 发表时间: 2018/01
类型:期刊论文 为本人加分:5265.123519
贡献度:共同通讯作者
7 Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shan..
来源:BMC HEALTH SERV RES( P 1472-6963 E ) 发表时间: 2010/07
类型:期刊论文 为本人加分:4869.113371
贡献度:单独第一作者;单独通讯作者
8 Complications of diabetes in China: health system and economic implications
来源:BMC PUBLIC HEALTH( P E 1471-2458 ) 发表时间: 2019/03
类型:期刊论文 为本人加分:4646.451064
贡献度:单独通讯作者
9 An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
来源:VALUE HEALTH( P 1098-3015 E ) 发表时间: 2009/11
类型:期刊论文 为本人加分:3420.805106
贡献度:单独第一作者;单独通讯作者
10 Does Economic Incentive Matter for Rational Use of Medicine? China's Experience from the Essenti..
来源:PHARMACOECONOMICS( P 1170-7690 E 1179-2027 ) 发表时间: 2014/03
类型:期刊论文 为本人加分:2837.569508
贡献度:共同通讯作者